Arvinas and Novartis to Develop and Commercialize PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer April 16, 2024
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated April 16, 2024
OSE Immunotherapeutics Receives €8.4 M in Public Funding for Registrational Ph 3 Trial of Cancer Vaccine Tedopi® in Lung Cancer April 16, 2024
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 April 16, 2024
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer April 16, 2024
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2 April 16, 2024
Clinical development of voruciclib to be advanced and new formulation of ME-344 to be enabled April 16, 2024
First Patient Dosed in First-in-Human Ph 1/2 Trial of BBI-825 in Patients with Resistance Gene Amplifications April 16, 2024
Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen + Pembrolizumab for the Treatment of Recurrent Ovarian Cancer Announced April 16, 2024
Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with R/R EBV+ PTCL Announced April 16, 2024
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN (nadofaragene firadenovec-vncg) in 2 Patient Cohorts April 16, 2024
Initial Data Reported from Clinical Study Evaluating ME-344 + Avastin in Relapsed Metastatic CRC Patients April 16, 2024
Type C Meeting Requested to FDA Toward Registration-Enabling Trial for Pelareorep in Breast Cancer April 16, 2024
Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression April 16, 2024
FDA Clearance To Initiate Ph 1/2 Clinical with TTX-MC138 in Advanced Solid Tumors Announced April 16, 2024
FDA accepts NDA for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers April 16, 2024
